As the crisis of european debt intensified, and the haze of global financial crisis is not gone, exert tremendous pressure and risk  to Chinese merchandise exports. However, there are rigid requirements of pharmaceutical intermediates bulk drugs import and export trade was still able to continue its active and prosperous state. This is the recently held 67th China International Fair on bulk drugs intermediates, packaging equipment, interviewed guests to pass information to reporters.
Peak and by the expiration of the patent medicine States to strictly control medical costs and other factors, the global generics market demand to expand. This gives Chinese products into the international pharmaceutical market offers opportunity and space, especially in the economic downturn situation gave birth to the transfer of industries, but also to China's import and export pharmaceutical products to the rapid development. Customs data show imports of commodities API to maintain steady growth, the growth rate of imports is roughly equivalent to the growth rate of exports. The first eight months of this year exports of pharmaceutical composition, decrease in the proportion of chemical raw materials, accounting for 77%, is still in an absolutely dominant position; class of chemical medicines risen to second place, accounting for 9.72%; biochemical proportion dropped to third place, accounting for 8.64%.
Export commodities, antibiotics, vitamins, resveratrol, amino acids, organic acids and animal organ extract biochemical export of bulk drugs is the subject. While no change in bulk low value-added export-oriented products, the situation, but there has been change in importance. And sweeteners, anti-viral (anti-AIDS), cardiovascular drugs, spices class, hormones gradually revealed a strong API. In 2010, total exports sweeteners $ 670 million, cardiovascular medicines exported $ 1.2 billion, exports of hormone medicines for the $ 500 million, exports of spices like $ 150 million anti-viral medicines exported $ 233 million. Throughout recent years, Chinese exports of bulk drugs intermediates, with exclusive, resource-based bulk drug prices continue to rise, such as heparin; the other hand, the advantage of the same type of China-exclusive API, because of overcapacity or excessive domestic competition caused by changes in product structure, causing the decline in export prices or shrinking turnover, such as vitamin C and penicillin. Published data on the current analysis, pharmaceutical raw materials like exports continue to grow, import and export is expected this year is expected to exceed last year, a new record high. Among them, bulk drug raw material exports rose less or more, import and export of Western medicine show very well.
Despite the recent normalization of international trade friction was the trend of negative factors facing the international trade increased, but exports are still promoting the international pharmaceutical companies to a higher stage of development of the main driving force. Future field of foreign trade enterprises in the face of difficulties and challenges will be significantly increased. Health Insurance Association figures show that China, as of the end of 2010, China has exported pharmaceutical companies 32,561, of which exports more than $ 1 million 4,666 enterprises, accounting for 14.3%; import business 16,210, of which imports more than $ 1 million business 1,676, accounting for 10.3%. However, according to some feedback from the participating companies, the current foreign orders are to small and short-term development of the trend. Such as energy prices, transportation costs increase the cost of exports, plant extracts trade in the euro area highlights the negative factors such as exchange rate risk still exists. Insiders pointed out that raw material prices, shorten delivery time, there is the expected appreciation of the RMB exchange rate and other conditions, resulting in increased pressure on business costs, increasing profit margins thin. Statistics show that 50% of the foreign production of pharmaceutical companies profit margin of 5% or less, of which 20% of the enterprises only 1%.
From exporting countries, Europe, the United States, India, Japan and other traditional export markets ranked ranking; to ASEAN, Russia and other emerging markets, exports increased considerably. American and European countries is still the main source of imports. Some experts pointed out that the bulk drugs and pharmaceutical products import and export volume U.S. $ 100 million over 15 enterprises, mainly in multinational companies to the Chinese joint venture or sub-packaging imported bulk drugs, formulations with a semi-finished commodities. In the declining U.S. dollar against the RMB exchange rate on the occasion, a corresponding decline in the cost of imports, so the source of Chinese imports of pharmaceutical products market competitiveness will be enhanced. But can not be ignored is that multinational strategy is the capital returned to the parent company or overseas company, the formation of the phenomenon of foreign earnings within the loss on the surface of the loss of interest in China, in fact, pharmaceutical raw materials the parent company is not lost, but the local joint venture in China to pay the high cost of imports.
International generics market and industry needs to expand, as China, India, China pharmaceutical industry to provide an unprecedented opportunity for development. As China's second largest export destination, the Indian pharmaceutical industry and China's API has a strong interdependence, China's pharmaceutical industry in India is also important to be one of the parties, during which a variety of trade disputes also occurred due to this dual identity. In the 67th China International Fair APIs intermediate packaging equipment, co-organizer of a special report in the Indian project (SIPP, Sino-IndiaPartnershipProgram) exhibition and forum held in the second session of the India, as has been interested in entering or Chinese companies entering the Indian market to provide a deeper understanding of India platform. According to statistics, the export of bulk drugs in India is mainly antibiotics, antibiotic intermediates, docetaxel hormones and antipyretic pain (non-steroidal anti-inflammatory drug) class. Among them, antibiotics and intermediates accounted for 53% of the amount of citric acid and other additives in the number accounted for 32% of the share, is the largest of the two categories of export products. However, as many representatives of the participating companies said: India, the bulk of Chinese exports are still concentrated in lower-value species, small and larger profit margins of APIs and intermediates. According to statistics, in 2010 exported more than 100 tons of a total of 78 species, including citric acid, p-aminophenol glucose is more than 10,000 tons of bulk drugs. There are 68 kinds of bulk drugs exports over $ 5 million, more prominent is the 6-APA, with exports amounting to $ 160 million, while the penicillin industrial salt, zidovudine, erythromycin thiocyanate ,7-ACA, amino phenol, GCLE, azithromycin is more than $ 50 million. Source:http://www.cospcn.com